Clinical Trials Logo

Distal Esophageal Adenocarcinoma clinical trials

View clinical trials related to Distal Esophageal Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01757171 Completed - Clinical trials for Gastric Adenocarcinoma

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Start date: December 2012
Phase: Phase 2
Study type: Interventional

Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks, as is the standard administration dose and schedule. This application is a non-labeled indication for cabazitaxel and will inform future drug development in gastroesophageal malignancies, where docetaxel remains an approved first line agent, but is not routinely used due to excessive toxicity and marginal efficacy. At the conclusion of this study, we hope to demonstrate activity of single agent cabazitaxel in refractory gastric cancer, with preferential activity in one or more gastric cancer subtypes